BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/26/2014 3:10:00 PM | Browse: 1104 | Download: 1055
Publication Name World Journal of Hepatology
Manuscript ID 8207
Country/Territory India
Received
2013-12-20 12:08
Peer-Review Started
2013-12-22 19:47
To Make the First Decision
2014-03-12 17:09
Return for Revision
2014-03-24 08:10
Revised
2014-04-11 14:55
Second Decision
2014-05-29 08:47
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2014-05-29 09:32
Articles in Press
2014-05-29 10:50
Publication Fee Transferred
Edit the Manuscript by Language Editor
2014-06-11 13:23
Typeset the Manuscript
2014-07-22 17:20
Publish the Manuscript Online
2014-07-25 16:43
ISSN 1948-5182 (online)
Open Access
Copyright
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Clinical Trials Study
Article Title Pegylated interferon alfa-2b plus ribavirin for treatment of chronic hepatitis C
Manuscript Source Unsolicited Manuscript
All Author List PN Rao, Abraham Koshy, Jacob Philip, Narayanan Premaletha, Joy Varghese, Krishnasamy Narayanasamy, Samir Mohindra, Nitin Vikas Pai, Manoj Kumar Agarwal, Ashoknanda Konar and Hasmukh B Vora
Funding Agency and Grant Number
Funding Agency Grant Number
Virchow Biotech Private Limited, Hyderabad, India
Corresponding Author PN Rao, MD, DM, Department of Gastroenterology, Asian Institute of Gastroenterology, 6-3-661, Somajiguda, Hyderabad 500082, India. pnrcraig@gmail.com
Key Words Hepatitis C virus; Genotype; Peginterferon alfa-2b; Ribavirin; Treatment
Core Tip In a multicenter study, the safety and efficacy of pegylated interferon alfa-2b, indigenously developed in India, plus ribavirin was evaluated on 100 hepatitis C virus (HCV) patients with genotypes 1, 2, 3, and 4. Eighty-two patients completed the study. Most patients had mild-to-moderate adverse events, although 11 serious adverse events were reported in 9 patients. However, only 4 of these were related to study medication. The percentage of serologic response (rapid virologic response, early virologic response, and sustained virologic response rates) of patients was similar to that reported in published studies. In conclusion, peginterferon alfa-2b, developed in India, is a safe and cost-effective drug in the treatment of Indian patients with HCV infection.
Publish Date 2014-07-25 16:43
Citation Rao PN, Koshy A, Philip J, Premaletha N, Varghese J, Narayanasamy K, Mohindra S, Pai NV, Agarwal MK, Konar A, Vora HB. Pegylated interferon alfa-2b plus ribavirin for treatment of chronic hepatitis C. World J Hepatol 2014; 6(7): 520-526
URL http://www.wjgnet.com/1948-5182/full/v6/i7/520.htm
DOI http://dx.doi.org/10.4254/wjh.v6.i7.520
Full Article (PDF) WJH-6-520.pdf
Full Article (Word) WJH-6-520.doc
Manuscript File 8207-Review.docx
Answering Reviewers 8207-Answering reviewers.pdf
Biostatistics Review Certificate Biostatistician_Review_Report_20131219123957.pdf
Copyright License Agreement 8207-Copyright assignment.pdf
Institutional Review Board Approval Form or Document Ethics_Committee_20131219123916.pdf
Peer-review Report 8207-Peer review(s).pdf
Scientific Misconduct Check 8207-CrossCheck.jpg
Scientific Editor Work List 8207-Scientific editor work list.pdf